Opthalmology Web

Date: May 03 - 07, 2026 Location: Denver, CO Type: Annual Meeting Organizer's Description: ARVO’s Annual Meeting is the premier global gathering for eye and vision scientists, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. For 2026, the Meeting will be hosted May 3 - 7 in Denver, Colo. Please visit the official event page for more information. View Event Website

ASCRS 2026 is an annual event organized by The American Society of Cataract and Refractive Surgery (ASCRS) and the American Society of Ophthalmic Administrators (ASOA). Please visit the official event page for more information.

AAO 2025 is an annual meeting organized by the American Academy of Ophthalmology. Please visit the AAO official event page for more information.

Researchers led by Cornell University and supported by the National Eye Institute have developed a 3D “eye-on-a-chip” platform that replicates ocular fluid dynamics, using it to uncover the signaling mechanism driving steroid-induced glaucoma. Reported in Nature Cardiovascular Research, this work addresses limitations of traditional animal models and 2D cultures, which inadequately capture the human eye’s anatomical complexity and physiological responses.

Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities.

NIH researchers have developed a new surgical method to implant multiple retinal tissue grafts, potentially expanding treatment options for dry age-related macular degeneration (AMD). The approach, demonstrated in animal models, allows for broader retinal coverage and enables side-by-side comparisons of graft integration. Current techniques permit only a single graft, limiting therapeutic potential and evaluation.

A new NIH-funded study from Johns Hopkins’ Wilmer Eye Institute suggests that low blood sugar may damage the blood-retinal barrier, which regulates essential exchanges in the retina. Researchers observed this effect in diabetic mice, offering new insight into how hypoglycemia may contribute to diabetic retinopathy. This condition, common in both type 1 and type 2 diabetes, can lead to irreversible vision loss if untreated.

Eversight, a global eye bank and full-service eye and vision research partner, today announced it is part of a major undertaking that will bring together more than 40 scientists, doctors and industry experts hand-picked from around the country to make vision-restoring whole eye transplants a reality. Eversight will contribute its expertise in eye banking and vision research to the six-year, multimillion-dollar project.

NIDEK CO., LTD., a global leader in the design, manufacture, and distribution of ophthalmic, optometric, and lens edging equipment, is pleased to announce the launch of the NP-T Preloaded Toric IOL Injection System. Although previously only available in Japan, the NP-T will now be available globally. The NP-T is a fully preloaded injection system with an aspheric hydrophobic soft acrylic toric lens that provides superior operability and reliable intracapsular fixation.

Date: Jun 25 - 28, 2025 Location: Honolulu, HI Type: Annual Meeting Organizer's Description: Immerse yourself in a vibrant community of eye care professionals and glaucoma specialists from around the globe to discuss the latest advancements in research and treatment. Our program features a diverse variety of thought-provoking sessions, workshops, and panel discussions aimed at enhancing your clinical skills and broadening your perspective.